Exclusive By Damian Garde Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
First Opinion By Dorothy Pomerantz 23andMe had devastating news about my health. I wish a person had delivered it
Pharmalot By Ed Silverman Merck reaches deal with Austrian antitrust regulators over ‘predatory’ pricing for a cancer drug
Pharma By Andrew Joseph José Baselga, renowned cancer researcher and AstraZeneca oncology R&D head, dies at 61
Health By Elizabeth Cooney Early trial shows promise aiming a modified cold-sore virus against brain tumors in children
Pharmalot By Ed Silverman Clinical study reports hold more details about the side effects of cancer drugs
Politics By Lev Facher Inside the White House’s push for a new, $6.5 billion agency aimed at curing cancer
Biotech By Adam Feuerstein Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer
Biotech By Adam Feuerstein The biotech scorecard for the second quarter: 18 stock-moving events to watch
Pharmalot By Ed Silverman FTC seeks to block Illumina from buying Grail, citing threats to competition
Biotech By Adam Feuerstein FDA approves first personalized cell therapy for patients with multiple myeloma
Biotech By Andy Rosen — Boston Globe Broad Institute launches $300 million effort to harness AI to fight diseases
Pharma By Matthew Herper and Damian Garde After leading a corporate turnaround, a swashbuckling CEO flies AstraZeneca into turbulence
Health By Meghana Keshavan What ‘Beans’ taught her parents about pediatric cancer, the need for research, and patient advocacy
Biotech By Adam Feuerstein A Rubius drug derived from red blood cells produces anti-tumor responses — and more questions
Pharmalot By Ed Silverman Pharmalittle: U.S. sits on millions of AstraZeneca vaccine doses; WTO again fails to act on Covid-19 proposal
Biotech By Adam Feuerstein With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image
A STAT Investigation By Casey Ross and Mario Aguilar Inside the fall of Watson Health: How IBM’s audacious plan to ‘change the face of health care’ with AI fell apart
Politics By Nicholas Florko Janet Woodcock revolutionized the way the FDA reviews cancer drugs, inspiring her supporters and raising concerns for detractors
Biotech By Matthew Herper Moncef Slaoui, departing Warp Speed, raises $250 million to test his R&D philosophy in a new company
A STAT Investigation By Casey Ross Could AI tools for breast cancer worsen disparities? Patchy public data in FDA filings fuel concern